Eli Lilly and Company vs Novo Nordisk A/S: Stock Comparison
Share price, earnings, valuation and dividends side by side.
Eli Lilly and Company has a market cap of $1.27T and Novo Nordisk A/S $178B, so Eli Lilly and Company is about 7.2 times the size of Novo Nordisk A/S.
Revenue growth (YoY) is +49.6% for Eli Lilly and Company and +5.6% for Novo Nordisk A/S.
Operating margin is 49.7% for Eli Lilly and Company and 43.1% for Novo Nordisk A/S.
The P/E ratio (TTM) is 45.3x for Eli Lilly and Company and 10.1x for Novo Nordisk A/S.
Dividend yield is 0.49% for Eli Lilly and Company and 4.40% for Novo Nordisk A/S.
In each row, the better figure is highlighted based only on the number itself. This does not say which is the better investment.
| LLYEli Lilly and CompanyHealthcare | NVONovo Nordisk A/SHealthcare | |
|---|---|---|
| Basics | ||
| Market cap | $1.27T | $178B |
| Share price | $1,354.00 | $40.31 |
| 1-year return | +45.3% | −12.2% |
| 5-year return | +434.7% | −23.1% |
| Valuation | ||
| P/E (TTM) | 45.3x | 10.1x |
| Forward P/E | 38.7x | 1.8x |
| P/S | 16.0x | 3.6x |
| P/B | 35.6x | 5.3x |
| EV/EBITDA | 30.5x | 7.1x |
| Profitability | ||
| Revenue (TTM) | $79.7B | $49.1B |
| Gross margin | 83.4% | 80.6% |
| Operating margin | 49.7% | 43.1% |
| Net margin | 33.5% | 35.3% |
| ROE | 92.6% | 59.1% |
| Growth | ||
| Revenue growth (YoY) | +49.6% | +5.6% |
| Revenue CAGR (5Y) | +21.6% | +19.5% |
| EPS CAGR (5Y) | +28.8% | +20.6% |
| Dividends & balance sheet | ||
| Dividend yield | 0.49% | 4.40% |
| Years of dividend growth | — | — |
| FCF yield | 1.6% | 4.2% |
| Debt/equity (lower = less debt) | 1.62x | 0.63x |
Other comparisons
Listed mechanically from public data. Not a recommendation to buy or sell any security.